Swicorp, an investment firm focused on the Middle East, North Africa and Turkey, has invested in Egyptian ophthalmological pharmaceuticals manufacturer Orchidia Pharmaceutical Industries. The investment, structured through Swicorp’s Intaj II investment fund, is intended to enable Orchidia to accelerate growth through the launch of new products and expansion to new markets, such as Saudi Arabia. Financial details of the transaction were not disclosed.